Reproductive health should be addressed from the time of diagnosis of cystic fibrosis and annually thereafter, with a more ...

The Yukon government says work is underway to add cystic fibrosis drug Alyftrek to its drug formulary. This comes as ...

The board of directors of Royalty Pharma plc (Nasdaq: RPRX) has approved the payment of a dividend for the third quarter of 2026 of $0.235 per Class A ordinary share.

More than a decade after the PharmaGate scandal, South Africa still grapples with necessary reforms to its patent laws, ...

How much a stock's price changes over time is important for most investors, since price performance can both impact your ...

First, let's take a look at Vertex's portfolio and general situation prior to the Crinetics move. As mentioned, the biotech is the global CF leader, specializing in CFTR modulators. These therapies ...

Vertex Pharmaceuticals Incorporated (Nasdaq: VRTX) today announced data demonstrating the potentially transformative impact of treating cystic fibrosis (CF) with ALYFTREK ® ...

Thanks to booming sales of blockbuster obesity and diabetes treatments, the amount that Americans spent on prescription drugs this year is on track to surpass $1 trillion, according to a report ...

At Yahoo Finance, you get free stock quotes, up-to-date news, portfolio management resources, international market data, social interaction and mortgage rates that help you manage your financial life.

Royalty Pharma Plc engages in the provision of drug development services. It operates as a funder of innovation across the biopharmaceutical industry, collaborating with innovators from academic ...

There are close to 40,000 children and adults living with cystic fibrosis in the US. Credit: HobbitArt/Shutterstock.com. The Cystic Fibrosis Foundation will supply up to $13m of funding to SpliSense, ...

When wonder drug Trikafta arrived just in time for Noah Harrington-Ashton’s birthday celebrations, this Christchurch family knew they had to go big. Photo / Selina Nunn For most toddlers, turning two ...